Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada

PURPOSE: High‐strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing. METHODS: We conducted a longitudinal study among patients receiving p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pharmacoepidemiol Drug Saf
Main Authors: Martins, Diana, Khuu, Wayne, Tadrous, Mina, Juurlink, David N., Mamdani, Muhammad M., Paterson, J. Michael, Gomes, Tara
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518867/
https://ncbi.nlm.nih.gov/pubmed/30873707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4764
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki